Italia markets open in 41 minutes

CannBioRx Life Sciences Corp. (ATNFW)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
0,8500+0,0500 (+6,25%)
Alla chiusura: 03:38PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,8000
Aperto1,0150
Denaro0,9201 x 900
Lettera1,1800 x 1100
Min-Max giorno0,8000 - 0,9577
Intervallo di 52 settimane0,8000 - 0,9577
Volume38.412
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

    PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today provided follow-up information on the top line results of Oxford University and the Company’s Phase 2b clinical trial for Dupuytren’s disease announced on December 1, 2021. Dr. James Woody, 180 Life Sciences Chi

  • GlobeNewswire

    180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

    ‘Cellular and Molecular Profiling of Dupuytren’s Disease: From the Lab to the Clinic’ Presented Wednesday, December 1, 2021, at 3pm ESTPALO ALTO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that Professor Jagdeep Nanchahal from the University of Oxford, a

  • GlobeNewswire

    180 Life Sciences Corp. Expands Patent Portfolio

    New IP Relates to a Method for Treating Chronic Pain or Associated Conditions/Symptoms with Novel Compositions Including Certain Phenyl Substituted Cyclohexenyl Compounds Related to Cannabidiol (CBD)PALO ALTO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced th